The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. This molecule targets the immune system to promote repair after brain trauma. The therapy aims to reduce stimulate the immune cells and enhance neurological recovery. We also work to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair. Expertise is sought in polysaccharide chemistry and extraction of molecules at pharmaceutical grade.
Exposición Huella Europa
Con motivo del 40º aniversario de la adhesión de España a la Unión Europea y en el marco del 40º aniversario de la Universidad de Castilla-La Mancha (UCLM), la institución organiza una jornada conmemorativa dirigida a la comunidad universitaria y a los agentes...
Ene 30, 2026
















